Baxter International Inc.
HealthcareNYSE:BAX · New York Stock Exchange
+$0.37 today
Vol 6.28M · Avg 7.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.6%
avg 9.2%
ROIC
-1.8%
avg 3.5%
ROA
-4.8%
avg 5.3%
Analysis
ROIC is currently the strongest return metric at -1.8% versus its period average of 3.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrew Hider | Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director | $3.49M | — | 49 | $572,239.00 | 0.11% |
Cynthia Carlisle | Executive Vice President & Chief Human Resources Officer | $1.99M | — | 50 | $17,806.00 | <0.01% |
Joel T. Grade | Advisor | $1.35M | — | 55 | $271,674.00 | 0.05% |
David S. Rosenbloom | Executive Vice President & General Counsel | $1.18M | — | 66 | $72,804.00 | 0.01% |
Maria Soriano | Group President of Infusion Therapies & Platforms | $1.10M | — | — | $75,045.00 | 0.01% |
Charles Rusty Patel | Senior Vice President & Chief Information Officer | — | — | 56 | — | — |
Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | — | — | — | — | — |
James W. Borzi | Executive Vice President & Chief Supply Chain Officer | — | — | 63 | $31,120.00 | <0.01% |
Steven Wallace | President of Advanced Surgery & Commercial Excellence | — | — | 45 | $70,282.00 | 0.01% |
Anita A. Zielinski | Senior Vice President, Interim Chief Financial Officer, Chief Accounting Officer & Controller | — | — | 53 | $30,375.00 | <0.01% |
Kevin Moran | Vice President & Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -25.0% | +1.6% (13yr)2 analysts |
| Revenue | N/A | N/A | -10.6% | +1.4% (13yr)8 analysts |
| Net Income | N/A | N/A | -25.3% | +1.0% (13yr)8 analysts |
| EBIT | N/A | N/A | -45.8% | N/A8 analysts |
Analysis
Recent growth has been strongest in Revenue at -10.6% over three years. Forward estimates point to EPS at +1.6% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
Masimo Corporation
NASDAQ:MASI
$9.42B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
Qiagen N.V.
NYSE:QGEN
$7.64B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Repligen Corporation
NASDAQ:RGEN
$7.37B
Avantor, Inc.
NYSE:AVTR
$6.41B
Hims & Hers Health, Inc.
NYSE:HIMS
$5.98B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages BAX?
Baxter International Inc. (BAX) lists 11 active executives. The top listed executive is Andrew Hider, Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director.
Are BAX insiders buying or selling?
Recent insider activity shows net buying of $37.23M.
Explore More
Continue the stock analysis
Jump to another research area for this company.